Vygon has announced its acquisition of Stiletto, which the company describes as a new generation of extended-dwell catheters integrating SlipStream technology, from Avia Vascular.
A press release notes that this strategic acquisition enhances Vygon’s leadership in vascular access and supports its ambition to accelerate growth in the USA, where extended-dwell catheters represent a significant and rapidly expanding segment of the market. Financial details were not disclosed.
The Stiletto extended-dwell catheter (EDC) is a sterile, peripherally inserted single-use
device designed for mid-duration therapies (<28 days). SlipStream is a patented insertion system designed to replace the traditional Seldinger technique for extended-dwell catheters.
“Stiletto closes a critical gap in our vascular access offering,” said Thomas Walter, chief
corporate officer, international business and offer development at Vygon. “Its SlipStream technology will reshape the way extended-dwell catheters are inserted, presenting clinicians with a safer, more intuitive technique and delivering significant improvements in patient comfort, safety and care efficiency, fully aligned with Vygon’s mission to value life.”
Vygon notes that, by eliminating guidewires and reducing procedural steps, SlipStream offers clinicians a simpler, safer and more intuitive technique, while delivering significant clinical benefits for patients.
“This acquisition is a decisive step for Vygon as it enhances our leadership in vascular access,” said Ludovic Richard-Vitton, CEO of Vygon. “By integrating Stiletto into our portfolio, we reinforce our position in this sector, significantly strengthening it in the US, the world’s largest and most dynamic market for midline and extended-dwell catheters.”
